188Re-HEDP therapy in the therapy of painful bone metastases
For bone-targeted radionuclide therapy (BTRT), different commercial radiopharmaceuticals are available such as strontium-89, 186Rhenium-hydroxyethylidene diphosphonate (186Re-HEDP), Samarium-153-ethylenediamine tetramethylene phosphonic acid, and radium-223. Unfortunately, the commercial available r...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2018-01-01
|
| Series: | World Journal of Nuclear Medicine |
| Subjects: | |
| Online Access: | http://www.wjnm.org/article.asp?issn=1450-1147;year=2018;volume=17;issue=3;spage=133;epage=138;aulast=Liepe |